Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Rapid Ebola preparedness and antiviral/vaccine development

May 26, 2026

SwRI and Texas Biomed are collaborating to test AI-identified antiviral compounds against Ebola virus, targeting the Bundibugyo species as the strain resurfaces in the Democratic Republic of...

Neonatal sepsis detection using AI in NICUs

May 26, 2026

Researchers unveiled an AI system intended to provide just-in-time, risk-stratified evaluations for neonatal sepsis in neonatal intensive care units. The goal is earlier detection during the...

Clinical trial and diagnostics expansion in women’s health biomarkers

May 26, 2026

Aspira Women’s Health signed a deal with Cleveland Clinic to expand access to patient samples and accelerate the clinical validation of multiomic diagnostics in women’s health. The collaboration...

Biotech regulation: COINS Act expansion discussion and China IIT rules

May 26, 2026

Two policy developments are reshaping the regulatory and compliance backdrop for biotech dealmaking tied to China. A separate report said calls for expanding the COINS Act are growing, with...

FDA approval milestone in mantle cell lymphoma

May 26, 2026

The FDA approved Beqalzi (sonrotoclax), described as the first BCL2 inhibitor specifically approved for relapsed or refractory mantle cell lymphoma after at least two prior lines of systemic...

Cancer immunotherapy and tumor recognition via antibody conjugates

May 26, 2026

A research report highlighted how platinum-antibody conjugates are designed to enhance tumor recognition and immune system engagement, aiming to broaden benefit from immune checkpoint inhibitors....

Medtronic expands neuromodulation with SPR Therapeutics acquisition

May 26, 2026

Medtronic agreed to buy SPR Therapeutics for $650 million, strengthening its pain management portfolio by adding a peripheral nerve stimulation system designed for sustained pain relief. The deal...

Antibody distribution partnership in molecular oncology diagnostics

May 26, 2026

Eurobio Scientific struck a distribution agreement with Canhelp Genomics for two molecular oncology assays across the UK, EU, and Benelux. The partnership covers the Canhelp-Uca urine assay for...

Gene-editing for LDL lowering moves through early clinical readouts

May 26, 2026

Eli Lilly reported early Phase 1 results for its VERVE-102 base-editing program, saying a single infusion reduced LDL cholesterol by as much as 62% and sustained the effect for up to 18 months....

Lilly accelerates infectious-disease dealmaking with three vaccine acquisitions

May 26, 2026

Eli Lilly announced agreements to acquire three private vaccine developers—Vaccine Co., Curevo, and LimmaTech Biologics—expanding its infectious-disease pipeline through a series of transactions...

Regulators approve a new targeted BCL2 option for mantle cell lymphoma

May 26, 2026

The FDA granted accelerated approval to Beqalzi (sonrotoclax), becoming the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma after at least two prior...

Lung and heart disease science meets AI in Lilly-linked gene editing and broader data tools

May 26, 2026

Lilly’s Phase 1 base-editing results on VERVE-102 are paired with continued momentum in AI-enabled precision approaches for disease biology and clinical decision-making. Separate disclosures from...

New trials signal faster, smarter fetal risk monitoring with wearable ultrasound

May 26, 2026

Researchers published results supporting continuous fetal monitoring using a wearable ultrasound patch designed to reduce dependence on highly trained sonographers. The work—led by a team...

Targeted cholesterol medicine and cardiovascular prevention continue to expand

May 26, 2026

Lilly’s gene-editing LDL story is part of a broader cardiovascular prevention push that is increasingly shaped by genetics-driven mechanisms and one-time dosing concepts. In parallel, early-stage...

China biotech faces regulatory tightening for investigator-initiated trials

May 26, 2026

New rules in China are expected to tighten regulatory oversight of investigator-initiated trials (IITs) while clarifying how sponsors can operate legally across modalities beyond cell and gene...

Antibacterial development advances via Hong Kong IPO funding

May 26, 2026

Tennor Therapeutics priced an $80 million IPO in Hong Kong to fund its antibacterial pipeline, including rifasutenizol (TNP-2198), which the company says could support a targeted combination...

Innate immunity study identifies a new antifungal detection route in the mouth

May 26, 2026

Researchers reported that TREM2-positive macrophages detect candidalysin to trigger an early antifungal immune response during oropharyngeal candidiasis. The work, led by Yunsheng Liang at Central...

Oncology regimen refinement: durable response signals for KRAS inhibitor combinations

May 26, 2026

Kura Oncology disclosed early combination data showing darlifarnib paired with Bristol Myers Squibb’s Krazati delivered response rates up to 69%, according to the company. The update frames the...

Infectious disease M&A expansion

May 26, 2026

Eli Lilly moved to bulk up its infectious-disease pipeline, agreeing to acquire three companies in deals totaling up to $3.8 billion. The acquisitions target viral and bacterial pathogen R&D and...

US FDA approval for BCL2 inhibitor in mantle cell lymphoma

May 26, 2026

The FDA granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy,...